Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...

NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion.

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The Ipsos survey of 1,078 adults found 24 of people would use weight-loss jabs if they were provided for free by the health service.

Ozempic, Wegovy and Mounjaro are often the most popular weight loss drugs. While these medications help people lose weight, they have undesirable side effects. Now, scientists at the University of ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...